PALO ALTO, Calif.--(BUSINESS WIRE)--Digbi Health, a leader in Precision biology-based care for obesity, type 2 diabetes, and gastrointestinal health, is excited to announce its SEC-regulated raise. This initiative allows millions to invest in the company's mission to transform healthcare by expanding access to personalized, genetics-based, and gut microbiome-driven treatments.
Opening Equity Participation and Expanding Access to Care
For the first time, Digbi Health is offering equity participation to the public, democratizing an investment opportunity that was previously only available to venture capital firms. This SEC-regulated raise allows individuals to support Digbi Health's vision of making Precision Biology-driven care for obesity and digestive health accessible to millions by expanding insurance benefits and Medicare coverage.
"By offering investment opportunity to the public, we are not only expanding ownership but also accelerating our commitment to making Precision Biology treatments available to millions," said Ranjan Sinha, CEO of Digbi Health. "Our goal is to integrate personalized, genetics and microbiome-based programs into everyday healthcare, expanding coverage through insurance and Medicare so more people can benefit from advanced, data-driven care."
Transforming Health Care Through Innovation
Thirty-five million users already have access to Digbi Health's personalized programs through major health plans and employers.
With over $16 million in funding from leading venture capital firms, the company will further expand its reach. This Reg CF offering on StartEngine allows more individuals to support the company's groundbreaking work in bringing effective, personalized treatments for obesity and digestive health to millions.
About Digbi Health
Digbi Health pioneered Precision Biology, integrating gut microbiome, CGM, and genetics to holistically prevent and treat three of the top four most expensive healthcare conditions - Obesity, Cardiometabolic, and Digestive. Our innovative, proven approach is highly differentiated and resonates with employers and health plans seeking new ways to eliminate the scourge of point solutions and reduce healthcare costs, especially GLP-1-related drug costs.
Our competitive edge lies in our unique data and bioinformatics platform, consolidating millions of diverse data points across genetics, progression of gut microbiome, metabolic, health, and disease markers. This repository empowers us to personalize care, unearth patentable signatures, generate impactful health risk profiles, and stratify patient care accurately for treatment. Digbi's unique contactable data set appeals to top pharmaceutical and food companies, positioning us as a leader in the field.
This equity raise is being conducted in accordance with Regulation Crowdfunding (Reg CF), a provision enacted by Congress under the JOBS Act, and is fully compliant with the rules and regulations established by the U.S. Securities and Exchange Commission (SEC).
For more information on the equity raise and how to invest, visit https://www.startengine.com/offering/digbi-health
